At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 26 enrolled
Drug / intervention
Nintedanib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Relative Bioavailability of a Single Oral Dose of Nintedanib Given Alone and in Combination With Multiple Oral Doses of Rifampicin in Healthy Male Volunteers (an Open-label, Two-period, Fixed Sequence Phase I Trial)
In Brief
A Phase 1 clinical trial evaluating Nintedanib and Rifampicin for Healthy. Completed, enrolled 26 participants across 1 site.
Detailed Summary
To investigate the effect of the P-gp inducer rifampicin on the pharmacokinetic parameters of nintedanib
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesGermany
Collaborators--
Timeline
Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2013
First PostedJan 2013
Primary CompletionMar 2013
TodayJul 2026
First PostedJan 17, 2013
Enrollment StartJan 1, 2013
Primary CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 13.5 years ago
Interventions
Nintedanibdrug
single dose administration
Rifampicindrug
single dose once daily for 7 days
Nintedanibdrug
single dose administration